Sortilin and hypertension
- PMID: 36683537
- PMCID: PMC9976622
- DOI: 10.1097/MNH.0000000000000866
Sortilin and hypertension
Abstract
Purpose of review: The current review aims to present the latest scientific updates on the role of Sortilin in the pathophysiology of hypertension.
Recent findings: The main focus of this systematic overview is on the functional contribution of Sortilin to the pathogenesis of hypertension. Sortilin is a glycoprotein mostly known for its actions as a trafficking molecule directing proteins to specific secretory or endocytic compartments of the cell. Emerging evidence indicates that Sortilin is associated with pathological conditions, including inflammation, arteriosclerosis, dyslipidemia, insulin resistance, and vascular calcification. Most recently, Sortilin has been shown to finely control endothelial function and to drive hypertension by modulating sphingolipid/ceramide homeostasis and by triggering oxidative stress.
Summary: The latest findings linking Sortilin and hypertension that are herein discussed can inspire novel areas of research which could eventually lead to the discovery of new therapeutic strategies in cardiovascular medicine.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest
There are no conflicts of interest.
Figures
References
-
- Lin Q, Ye T, Ye P, et al. Hypertension in stroke survivors and associations with national premature stroke mortality: data for 2.5 million participants from multinational screening campaigns. Lancet Glob Health 2022; 10: e1141–e1149. - PubMed
-
- Fujii R, Hishida A, Nakatochi M, et al. Associations of genome-wide polygenic risk score and risk factors with hypertension in a Japanese population. Circ Genom Precis Med 2022; 15:e003612. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
